Patients (n) |
87 |
51 |
36 |
Age (years) (SD) |
57.88 (9.96) |
58.01 (8.98) |
57.71
(11.34) |
Male/Female (%) |
39.07/60.93 |
39.22/60.78 |
38.89/61.11 |
Creatinine (mg/dl) (SD) |
0.83 (0.27) |
0.89 (0.28) |
0.79
(0.27) |
eGFR (mL/min/1.73m2) (SD) |
88.10 (±26.47) |
82.81
(±28.33) |
92.72 (±25.19) |
Initiating treatment, n (%) |
|
|
|
Metformin
|
72 (82.75)
|
39 (76.47)
|
33 (91.66)
|
Sulfonylureas
|
23 (26.43)
|
13 (25.49)
|
10 (27.77)
|
DPP-4i
|
31 (35.63)
|
20 (39.21)
|
11 (30.55)
|
SGLT2i
|
31 (35.63)
|
15 (29.41)
|
16 (44.44)
|
Insulin
|
51 (58.62)
|
51 (100)
|
36 (0)
|
ACEIs/ARBs
|
68 (78.16)
|
43 (84.31)
|
25 (69.44)
|
Diuretics
|
50 (57.47)
|
29 (56.86)
|
21 (58.33)
|
Antihyperglycemic drugs (without insulin), n (%)
|
|
|
|
0
|
5 (5.74)
|
4 (7.84)
|
1 (2.77)
|
1
|
31 (35.63)
|
18 (35.29)
|
13 (36.11)
|
2
|
32 (36.78)
|
19 (37.25)
|
13 (36.11)
|
≥3
|
19 (21.84)
|
10 (19.60)
|
9 (25)
|
Glucose (mg/dl) (SD) |
174.22 (66.25) |
175.91 (72.79) |
162.89
(46.99) |
HbA1c (%) (SD) |
8.53 (1.91) |
8.87 (1.97) |
7.81 (1.42) |
Weight (kg) (SD) |
102.20 (19.64) |
98.68 (14.38) |
108.66
(26.02) |